Blog Posts

Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs

Boehringer Ingelheim on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals use contract pharmacies.

Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.

Please Login or Become a Paid Subscriber

Read More »

Infrastructure Bill Excludes Spread-Pricing Language That 340B Entities Oppose

An infrastructure-spending bill nearing a vote in the U.S. Senate excludes Medicaid managed care “spread pricing” language that 340B entities have been fending off since 2019.

340B covered entities dodged a bullet Sunday when U.S. Senate negotiators released the text of a $550 billion bipartisan infrastructure-spending bill. It did not contain Medicaid managed care “spread pricing” language that entities have been fending off since 2019. Entities

Read More »

The Power of Partnership: Work with an Administrator that Understands Independent Pharmacies

SPONSORED CONTENT

It is my pleasure to introduce our company to 340B Report’s readers. RxPreferred Benefits is a fully transparent 340B Administrator and Pharmacy Benefit Manager (PBM) founded, and solely owned, by independent pharmacy representatives. Privately held and headquartered in Nashville, TN, RxPreferred operates nationally, partnering with a wide range of clients including: 340B covered entities, self-funded employers, hospitals, health systems, hospices, pharmacies, brokers, and third-party administrators.

Zero Conflicts-of-Interest

Read More »

Young Firebrand Lawmaker Gets into Shouting Match with 340B Champion

U.S. Rep. Madison Cawthorn (R-N.C., left) and the staff of Rep. David McKinley (R-W.Va., right) allegedly got into "a back-and-forth" last week over Cawthorn's listing as a co-sponsor of 340B legislation that McKinley filed with Rep. Abigail Spanberger (D-Va.).

News organization Politico reports that U.S. Rep. Madison Cawthorn (R-N.C.) “got into a back-and-forth with” the staff of Rep. David McKinley (R-W.Va.) last week Thursday, July 29, over Cawthorn’s listing as a co-sponsor of legislation to protect 340B covered

Read More »

Distressed Critical Access Hospitals that Devolve to Stay Open Would Lose 340B Eligibility

A new federal law to help financially distressed rural hospitals stay open in a reduced capacity would not preserve the hospitals’ eligibility for 340B drug discounts.

A new federal law to help financially distressed rural hospitals stay open in a reduced capacity would not preserve the hospitals’ eligibility for 340B drug discounts.

Please Login or Become a Paid Subscriber to View this

Read More »

Feds and Lilly Make Their Case to Federal Judge in Key Hearing Today

U.S.District Judge Sarah Evans Barker held a hearing today in drug manufacturer Eli Lilly's 340B contract pharmacy lawsuit against HRSA.

Attorneys for the government and drug manufacturer Eli Lilly dueled over legality of 340B contract pharmacy requirements during a hearing before a federal district judge in Indianapolis today.

Please Login or Become a Paid Subscriber to

Read More »

Key GOP Congressman Opposed 340B Amendment to Spending Bill During Committee Hearing

Rep. Michael Burgess (R-Texas) this week cited ongoing 340B contract pharmacy litigation in cautioning against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber to View

Read More »

In AstraZeneca’s 340B Lawsuit, Focus Shifts to HRSA’s May 17 Violation Letter

AstraZeneca and the federal government have filed a new round of briefs in the drug manufacturer’s 340B contract pharmacy lawsuit.

AstraZeneca and the federal government have filed a new round of briefs in the drug manufacturer’s 340B contract pharmacy lawsuit, this round focused on the government’s May 17 letter telling the company its contract pharmacy actions are illegal.

Read More »

“Experience Verity 340B” Webinar Series August 3-5

SPONSORED CONTENT

Verity Solutions, the award-winning provider of 340B software and services, is releasing their next “Experience Verity 340B” webinar series on August 3-5, 2021.

Each 20-30 minute sessions is designed for anyone who wants to understand how their Covered Entity’s 340B program performance might be enhanced by Verity Solutions’ unique blend of cutting-edge software technology and advanced account management. Verity 340B industry experts will cover each

Read More »

340B Won’t be Overlooked if There’s a Grand Bargain on Drug Pricing, Analyst Predicts

340B “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicts.

The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform

Read More »
Generic selectors
Exact matches only
Search in title
Search in content